3,000% Growth Hidden In Plain Sight

• While the big 5 marijuana stocks bled cash and shed value, one quiet pot stock has been building a real business
• Out from the shadows… it’s the legal cannabis market investors have been seeking all along.
• While profits in Canada and California fizzled, a quiet corner of the U.S. sizzled.
• GTSIF‘s main asset is one of the market’s largest independent processors and number 6 on the top-10 list.

A secret corner of the vast American economy has exploded with 3,000% growth in just three years.^[1]

What’s shocking about the skyrocketing growth, is that it happened in a corner of a currently out-of-favor investment sector – legal cannabis.

That’s likely why the bulk of investors missed a small stock that’s riding this momentum to fantastic growth.

GTSIF‘s main asset revenues have been on fire, up 2,269%, in the past three years {2015-2018]. Last year, its sales topped $14.5 million.^[2]

And, unlike so many companies in the sector, this looks as if it could be the year the company is solidly profitable.

There’s a powerful reason for the company’s soaring revenues and profit potential.

It is one of the largest independent marijuana processors in its market. It makes brand name products for both the medical and recreational markets.

Those include 2 million pre-rolled marijuana cigarettes each year (2.5 million in 2019).^[3]

Its market is Washington State, where recreational pot has been legal since 2012.

Meet A Thriving Legal-Marijuana Company In A Mature And Stable Marketplace

At this point, Washington is a thoroughly mature market and the world’s second oldest legal-marijuana marketplace.

And, that’s why, unlike the rest of North America’s helter-skelter legalized markets, a Washington-based company deserves your immediate attention.

The company is Cowlitz County Cannabis Cultivation, which is the main asset of Greenstar Biosciences, Corp. (GTSIF).

Investors who make their move into GreenStar now could be in for the ride of a lifetime.

That’s because GreenStar’s main asset has carved out an opportunity that could soon make 2018 revenue of $14.5 million look paltry.

(A note about the revenue figure. It comes from a corporate press release, but the State of Washington requires all cannabis companies to report sales and tax figures which list sales for Greenstar’s main asset, Cowlitz, at around $27.7 Million for 2018^[6]).

In what could be the year’s top industry coup, GreenStar just struck a deal that could make it a significant player on the global legal cannabis scene.

The deal is a 50/50 partnership in a breakthrough system for growing ultra-high-potency hemp rich with cannabinoids.

In other words, the pioneering technology grows hemp that super rich in one of today’s most in-demand nutritional supplements… CBD!

That, in turn, could put Greenstar Biosciences, Corp. (GTSIF) on a path that finds it emerging as the legal-cannabis industry’s next Charlotte’s Web (OTC:CWBHF).

GTSIF Looks As If It Could Be 2020’s Version of Charlotte’s Web With Initial Fundamentals That Suggest It’s Way Undervalued

CWBHF came public on August 30, 2018, at $5.40 a share. That was based on 2017 revenues of $40 million. In 2016, its revenues were $14.7 million. ^{[4] [5]}

And, to be honest, it’s unfair to Charlotte’s Web to compare it with GreenStar Biosciences.

That’s because GreenStar has something Charlotte’s Web lacked when it made its IPO… GreenStar has a solid foundation to build upon – its main asset has $14+ million in annual legal-marijuana sales.

Still, the comparison is what hints at the idea that GreenStar Biosciences (GTSIF) could be the investment find of a lifetime.

GreenStar trades for 5.5 cents a share as I write in late November… yes, that’s 5.5 cents!

The Comparison Is Stunning…
GreenStar Could Soon Be A $2.50 Stock

But, look how compared to the numbers Charlotte’s Web must have reported in its pre-IPO prospectus.

Charlotte’s Web reported $14.7 in 2016, and, in the year prior to its IPO, $40 million in 2017 revenues.

One GreenStar Biosciences asset reported $14.5 million in 2018, the year before it came public. ^[6]

And, has booked nearly $11 million in revenue in just the first half of 2019.^[7]

Based on CWBHF’s IPO, if this were August 2018, investors might have been all over GreenStar at $2.50.

You can get in at around 10 cents!

And, yes, that makes Greenstar Biosciences, Corp. (GTSIF) a penny stock.

And, frankly, that’s not a bad thing.

After all, recently, there have been few investments that paid off like penny pot stocks.

Blockbusters You Could Have bought For Pennies

Back in 2016, Cronos Group Inc (CRON), a Toronto-based company that invests in medical marijuana, was selling for only 33 cents per share.^[8]

As a penny stock, it didn’t get much respect.

But, CRON quickly rose to over $1.00 per share, tripling the money of early investors.

Yet it didn’t stop there.  CRON kept rising higher and higher, and then higher still.

By early 2019, this once-penny pot stock was selling for over $20 per share.^[9]

Then, investors who risked $3,000 on CRON when it was selling for $0.34 per share could have made between $94,058 and $173,470 in profits.

They could have multiplied their investment by between 31 and 56 times all by buying shares before the company is discovered.

American Made Bombshells

Another classic example is American Cannabis Company Inc (AMMJ).  For much of 2015 and 2016, it was trading at between 8 and 20 cents per share.

Then, in October 2016, the stock took off as the first wave of cannabis mania roiled the markets.

The stock shot up to a high of $2.05 before settling back down to between $0.40 and $1.40 per share.

Early investors, who got in around 10 cents, could have seen every $3,000 grow to between $42,000 (at $1.40 per share) and $60,000 (at $2.05).

In other words, gains of between 1,300% and 1,949%.

Cannabis Sativa Inc (CBDS) shared a similar story of explosive share prices.

In business since 2005, CBDS only went public three years ago.

In early 2016, CBDS was selling for just 35 cents per share but then soon shot up to as high as $7.80 per share – a gain of 2,128%.  Eventually, it settled back down to between $2 and $3 per share.

Had you risked $3,000 on the stock at 35 cents, you could have made between $14,142 and $63,857 in profits.

Mega Profits On The CBD Megatrend

And then there was CV Sciences (CVSI).

It’s not a pure cannabis play since it’s a pharma company moving into the CBD market.

Yet it illustrates the potential that penny cannabis stocks offer to shrewd investors.

Back in early 2016, you could have bought all the shares of CVSI you wanted for just 11 cents a share.

The stock traded between 20 and 30 cents for the next year or so, but then, in early 2018, took off.  It traded above $6.00 per share before it, too, pulled back.  It’s now trading around $3.10^[10] per share.

Yet had you invested $3,000 in CVSI before it was discovered, when it sold for 11 cents per share, you could have made between $81,818 and $163,600 in profits.

Again, that represents a gain of between 26 and 53 times your money over a 30-month period.

What these examples illustrate is the importance of buying penny pot stocks from legitimate businesses when they’re still selling at rock bottom prices.

They also show that investors are better off looking at established legal cannabis operations with a consistent history.

The stock today that fits that bill is, of course, Greenstar Biosciences, Corp. (GTSIF).

I’ve been an investment authority for more than 30 years, and I must say this is one of the very best, huge-upside young companies I have ever seen.

By the way, I’m James DiGeorgia, editor of the popular World Opportunity Investor advisory.

Over the years I’ve seen a lot. It’s why I’ve been a featured guest on CNBC, Fox Business, and am frequently quoted as an expert in The New York Times, USA Today, Los Angeles Times, Money magazine, The Chicago Tribune, and Barron’s, to name just a few.

I’m also the author of several best-selling books including The New Bull Market in Gold, The Rise of Gold in the 21st Century, The Global War for Oil, and The Trader’s Great Gold Rush.

And not to brag, but when President Trump’s good friend and Mar-a-Lago member Christopher Ruddy found his financial division in a rut, he brought me into the inner circle to energize them.

So, I am well-known for discovering stocks just as they hit the fast track for success.

#6 On The Top 10 List, Greenstar’s main asset, Cowlitz, is one of Washington State’s Largest Independent Processors

What put Greenstar Biosciences, Corp. (GTSIF) on the fast track to sudden success is that it recently signed on one of the fastest growing licensed cannabis processors in Washington State – Cowlitz County Cannabis Cultivation.

Based in Longview, Washington, Cowlitz was founded in 2015 by two entrepreneurial brothers, Cam and Jake Svenson. They saw Washington State’s 2012 legalization of recreational cannabis as an enormous opportunity — and seized it!

After cobbling together $15,000 in startup capital, the brothers launched one of the first fully licensed, 100% legal cannabis processing operations for Washington State’s burgeoning recreational market.

So, to make the distinction clear, via its Cowlitz County Cannabis Cultivation asset, GreenStar makes its money as a processor leveraging their product brands, and not as a grower.

That means it buys raw cannabis “flower” from growers in the area; then, it manufactures high-quality cannabis products (such as pre-rolled cigarettes) at affordable prices.  (Pre-rolled joints sell for around $20 retail for a pack of four.)

Under the brand names of Cowlitz Gold, Hi Guys, and Dab Dudes, the company also distributes cannabinoid powder, butane hash oil, and pre-rolls to 150 legal dispensaries in Washington State.

And as you might expect in a fast expanding market, sales have exploded from a few thousand dollars when the company first began anywhere from $1.5 million to $2.4 million per month.

Cowlitz is now one of the largest buyers of raw cannabis flower in Washington State, with 40 employees at its manufacturing facility in Longview.

Yet despite this rapid success, Greenstar Biosciences, Corp. (GTSIF), is almost wholly unknown outside the circle of its happy customers.

It’s a secret that’s bound to get out.

That’s because GreenStar has huge plans… what could be worldwide plans.

Getting In On The CBD Megatrend
With A Breakthrough Technology

In what can only be said to be an industry coup, Greenstar now has 50% ownership of a new proprietary grow technology, known as Micro-Pod Grow.

The breakthrough technology could reduce its costs for raw cannabis to an industry-low of just 10 cents per gram.

But, that’s not all.

GreenStar’s 50/50 deal with Indiana-based Progressive Herbs Micro-Pod technology resulted in a new subsidiary called Capri.

It will use the Micro-Pod Grow breakthrough to produce cannabis that is super saturated with CBD.

There’s no denying that CBD is a massive megatrend with few investable companies save for Charlotte’s Web.

From helping veterans overcome PTSD, to staving off cancer, to chronic anxiety and pain relief, to mundane uses such as reducing acne, CBD is being shown to improve human health and lifespans by offering remarkable new dimensions in non-pharmaceutical healthcare.^[11]

Because of that, enthusiasm for CBD is sweeping through the medical research community.

Currently, there are 42 active clinical trials for CBD’s effect on a host of dire clinical conditions such as brain injury, cancer of the pancreas, fast-growing brain tumors, and Parkinson’s Disease.^[12]

In all, it’s why the American CBD industry is now forecast to grow by as much as 3,556% during the next three years. That’s a leap from about $600 million in 2018 to $22 billion by 2022.^[13]

Thanks to its 50/50 deal with Progressive Herbs, there’s a great chance GreenStar Biosciences, Corp (GTSIF) could be in the heart of the CBD action.

GreenStar Biosciences Has Another Huge Investable Edge Washington State Has Slammed The Doors Shut On New Cannabis Businesses!

Greenstar Biosciences, Corp. (GTSIF) could represent one of the last authentic penny pot stock plays in Washington.

That’s because, in 2016, the State Legislature enacted a more comprehensive regulatory framework that makes it almost impossible for new cannabis businesses to enter the market.

For example,  the state agency that regulates cannabis sales, the Washington State Liquor and Cannabis Control Board, is currently no longer accepting any applications for new processor or cultivation licenses.^[14]

This has likely slammed the door and any new competition for the company’s lofty perch as a top 10 processor.

Moreover, and this is a biggie, Washington State’s cannabis sales, cultivation, and processing licenses are NOT transferable.

This not only enhances GreenStar Biosciences’ value… it could send it through the roof.

As a result, GreenStar Biosciences (GTSIF) represents an enormous, almost unprecedented opportunity to lock in immediate short-term profits while also being positioned for potentially life-changing long-term gains.

You can make your move now at what could be its all-time low around 10 cents.

• At that price, should GreenStar Biosciences mimic Charlotte’s Web and run to $2.50, then every $3,000 invested could soar to $75,000 – a 2,500% gain.
• If you wait and get in around 20 cents, then every $3,000 invested would grow $37,500, 1,250 gain.
• And if you wait to buy Greenstar Biosciences, Corp. (GTSIF) until 30 cents, then every $3,000 could become $25,000 – or a solid 833% gain.14.5